Caregen (CEO Yongji Jeong), a bio company specializing in peptides, announced on the 5th that it has applied for a patent for skin improvement and anti-aging technology using its metabolism-regulating peptide complex, Deglusterol.
Diglusterol is a health functional food ingredient that improves insulin sensitivity and reduces insulin resistance, helping to regulate blood sugar and maintain metabolic homeostasis. It was listed as a New Dietary Ingredient (NDI) by the US FDA in 2022. Since then, various studies and clinical observations, focusing on metabolic disorders, have confirmed its positive effects.
This patent application was based on research demonstrating that diglucesterol's metabolic regulatory function is closely linked to skin aging. Elevated blood sugar levels and tissue sugar accumulation induce glycation of skin proteins, which can damage collagen and elastin, leading to increased wrinkles, decreased elasticity, and pigmentation. Caregen explained that diglucesterol contributes to improving the whole-body metabolic environment by activating AMPK and increasing SIRT1 expression, and promotes collagen synthesis and reduces MMP activity by activating skin cells and inhibiting AGE accumulation.
Caregen stated that this patent clearly demonstrates that the peptide platform centered around diglucesterol can expand beyond metabolic health to skin improvement and anti-aging. Furthermore, diglucesterol is expected to find broader applications in the inner beauty (nutricosmetics) and anti-aging supplement markets, and even into the anti-aging food market.
“Diglusterol is a component that simultaneously targets metabolic health and skin aging,” said Caregen CEO Jeong Yong-ji. “Through this patent, we will strengthen the foundation for expanding the functional food and global anti-aging markets.”
- See more related articles
You must be logged in to post a comment.